Skip to main content
Michael Kaplitt, MD, Neurosurgery, New York, NY, New York-Presbyterian Hospital

MichaelKaplittMDPhD

Neurosurgery • New York, NY

Cerebrovascular Neurosurgery, Pain, Stereotactic & Functional Neurosurgery

Associate Professor of Neurological Surgery, Weill Cornell Medicine; Vice Chairman, Dept. of Neurological Surgery

Request Appointment

Overview of Dr. Kaplitt

Dr. Kaplitt combines surgical expertise with advanced training in state-of-the-art stereotactic techniques to provide patients with effective, minimally invasive treatments for degenerative disorders, including Parkinson’s disease, essential tremor, and dystonia. He also uses these methods to provide novel treatments for psychiatric disorders such as obsessive-compulsive disorder as well as for experimental treatment of major depression and drug addiction. In addition, he is an expert in the use of implanted devices for the treatment of medication-resistant complex pain, spasticity and adult hydrocephalus.

Dr. Kaplitt is also an expert in various surgical therapies for trigeminal neuralgia as well as novel therapies for more complex craniofacial pain. He is recognized for his contributions by leading medical and patient associations, and has repeatedly been named to Castle Connolly’s America’s Top Doctors and New York Metro Top Doctors and regularly appears on the New York Super Doctors list. He is a member of the Executive Committee of the American Society for Stereotactic and Functional Neurosurgery, the society for physicians who specialize in this type of surgery, and he is on the editorial board of the journal Stereotactic and Functional Neurosurgery, the primary international journal in this area.

Dr. Kaplitt has pioneered human gene therapy for neurodegenerative disorders, having performed as a student the first rodent study that used the adeno-associated virus (AAV) vehicle for gene transfer to the brain. He performed the world’s first human gene therapy procedure for Parkinson’s disease, and more recently helped to guide the first successful randomized, double-blind, sham-controlled trial of this experimental treatment, which was the first positive trial of this kind for gene therapy in any brain disorder. He is also pioneering the development of novel deep brain stimulation treatments for psychiatric diseases, including refractory drug addiction.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Chief Residency, Neurological Surgery, 1999 - 2000
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Neurological Surgery, 1996 - 2000
  • Rockefeller University
    Rockefeller UniversityPost-Doctoral Fellowship, Biochemical Genetics and Metabolism, 1995 - 1998
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Internship, Neurological Surgery, 1995 - 1996
  • Rockefeller University
    Rockefeller UniversityPost-Doctoral Fellowship, Neurobiology and Behavior, 1993 - 1995
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1995

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 1998 - 2025
  • CT State Medical License
    CT State Medical License 2022 - 2024
  • American Board of Neurological Surgery Neurological Surgery

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Super Doctor SuperDoctors.com
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Clinical Quantitative Susceptibility Mapping (QSM): Biometal Imaging and Its Emerging Roles in Patient Care  
    Gary M Brittenham, Apostolos John Tsiouris, Lawrence Tanenbaum, Ajay Gupta, Martin R Prince, Jonathan W Weinsaft, Susan A Gauthier, Brian H Kopell, Michael G Kaplitt, ..., Journal of Magnetic Resonance Imaging

Authored Content

  • Safe and Stable Noninvasive Focal Gene Delivery to the Mammalian Brain Following Focused Ultrasound RelatedApril 2018
  • Safe and Stable Noninvasive Focal Gene Delivery to the Mammalian Brain Following Focused Ultrasound RelatedApril 2018

Press Mentions

  • A Promising Trial Targets a Genetic Risk for Alzheimer’s
    A Promising Trial Targets a Genetic Risk for Alzheimer’sDecember 2nd, 2022
  • LEXEO Therapeutics to Present New Clinical Data from Its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
    LEXEO Therapeutics to Present New Clinical Data from Its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual MeetingOctober 5th, 2022
  • Can Ultrasound Help Treat Alzheimer’s?
    Can Ultrasound Help Treat Alzheimer’s?March 7th, 2022
  • Join now to see all

Grant Support

  • Gene Therapy for Huntington’s DiseaseNIH/NINDS2010–2015

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    MagnaCare PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Michael Kaplitt, Dr. Michael Kaplitt, MD, Dr. M Kaplitt